Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients

Next Previous
Trial Profile

A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 10 Dec 2022 Results of sub analysis from Global DRAGON study (n=30) assessing the efficacy and safety of erenumab 70 mg in adult chronic migraine patients, presented at the 16th European headache federation Congress.
    • 26 Apr 2022 Primary endpoint (Change from baseline in monthly migraine days during the last 4 weeks of the 12-week treatment period) has been met according to the results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 26 Apr 2022 Results assessing efficacy and safety of once-monthly subcutaneous erenumab 70 mg in adult patients with chronic migraine (CM) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top